• Novel Prognostic Classification of AML

  • Minimal Residual Disease

  • Bioinformatics

  • Chemogenomics

  • GELS


Acute Myeloid Leukemia (AML) is a particularly lethal form of cancer, with most patients dying within two years of diagnosis. It is one of the leading causes of death among young adults. Existing prognostic tests are often inaccurate, leaving doctors with no tools to guide their decision making about treatment options.

The project will help increase the survival rate of patients with acute myeloid leukemia by helping to determine treatment based on the genetic makeup of their leukemia cells. By giving hemato-oncologists access to more accurate tools, this project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. It can also help avoid unnecessary hospitalizations and treatments, while generating significant savings in health care expenditures.

The LEUCEGENE project is headed by Drs Guy Sauvageau (Project Leader, IRIC), Josée Hébert (Co-Project Leader, HMR Research Centre), Anne Marinier (Head Chemist, IRIC) and Sébastien Lemieux (Head of Bioinformatics, IRIC). It involves researchers from IRIC and HMR, as well as researchers from Université Laval and McGill University.


June 3, 2016 - Recent publication of the Leucegene team in Blood Cancer Journal
Maiga et al. published Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets in the scientific journal Blood Cancer Journal.

March 31, 2016 - An additional publication of the Leucegene team in Blood
Lavallée et al. published Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors in the scientific journal Blood.

March 14, 2016 - Recent publication of the Leucegene team in Blood
Lavallée et al. published RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature in the scientific journal Blood.

February 26, 2016 - Recent publication of the Leucegene team in Leukemia
Lavallée et al. published Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations in the scientific journal Leukemia.

Upcoming events

April 26, 2017
ASPET Annual Meeting, Chicago, IL, USA

December 3-6, 2016
58th ASH Annual Meeting, San Diego, CA, USA

Our Partners

Genome Canada Genome Quebec IRIC Amorchem BCLQ